Accessibility Menu
 
Bio-Rad Laboratories logo

Bio-Rad Laboratories

(NYSE) BIO

Current Price$280.82
Market Cap$8.12B
Since IPO (1980)+11,670%
5 Year-56%
1 Year+13%
1 Month+3%

Bio-Rad Laboratories Financials at a Glance

Market Cap

$8.12B

Revenue (TTM)

$2.58B

Net Income (TTM)

$759.90M

EPS (TTM)

$27.92

P/E Ratio

10.77

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$280.82

Volume

423,542

Open

$294.82

Previous Close

$281.42

Daily Range

$274.89 - $294.82

52-Week Range

$211.43 - $343.12

BIO: Motley Fool Moneyball Superscore

49

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio-Rad Laboratories

Industry

Life Sciences Tools and Services

Employees

7,400

CEO

Norman D. Schwartz

Headquarters

Hercules, CA 94547, US

BIO Financials

Key Financial Metrics (TTM)

Gross Margin

52%

Operating Margin

9%

Net Income Margin

29%

Return on Equity

11%

Return on Capital

2%

Return on Assets

7%

Earnings Yield

9.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.12B

Shares Outstanding

26.99M

Volume

423.54K

Short Interest

0.00%

Avg. Volume

291.53K

Financials (TTM)

Gross Profit

$1.34B

Operating Income

$270.50M

EBITDA

$475.90M

Operating Cash Flow

$532.20M

Capital Expenditure

$157.60M

Free Cash Flow

$374.60M

Cash & ST Invst.

$1.54B

Total Debt

$1.53B

Bio-Rad Laboratories Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$693.20M

+3.9%

Gross Profit

$345.20M

+1.0%

Gross Margin

49.80%

N/A

Market Cap

$8.12B

N/A

Market Cap/Employee

$1.05M

N/A

Employees

7,700

N/A

Net Income

$720.00M

+200.6%

EBITDA

$114.30M

+113.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$11.70M

-96.0%

Accounts Receivable

$472.50M

+4.4%

Inventory

$740.70M

-2.5%

Long Term Debt

$1.49B

+12.1%

Short Term Debt

$37.90M

-11.7%

Return on Assets

7.18%

N/A

Return on Invested Capital

2.28%

N/A

Free Cash Flow

$119.10M

+46.6%

Operating Cash Flow

$164.90M

+32.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATRAptarGroup, Inc.
$124.94+0.31%
CRLCharles River Laboratories International, Inc.
$167.74-9.23%
HSICHenry Schein, Inc.
$78.22+0.14%
MASIMasimo Corporation
$178.71+0.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.33+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.02-0.07%
TQQQProShares Trust - ProShares UltraPro Qqq
$59.22-0.02%
AALAmerican Airlines Group
$11.78+0.02%

Questions About BIO

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.